Glucagon-like-peptide-1 receptor (GLP-1R) agonists have become a first-line option for management of type 2 diabetes mellitus, and are now widely used in the management of obesity [31]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.